Skip to main content
Quest Diagnostics

Estimated National Hepatitis C Prevalence using Residual Sera from a National Commercial Laboratory – United States, November 2023–September 2024

Global Hepatitis Summit 2025

Los Angeles, CA, Mar 18-21, 2025

Poster presentation: Estimated National Hepatitis C Prevalence using Residual Sera from a National Commercial Laboratory – United States, November 2023–September 2024

Authors: Hofmeister MG, Zhong Y, Swanson BE, Barker LK, Symum H, Thompson WW, Kaufman HW,  Meyer WA III, Gupta N

Specialty: Infectious disease

Related content

Publication
Social Determinants of Hepatitis C Virus Infection in the United States, 2016–2021
Publication
Relationship Between Hepatitis C Virus (HCV) IgG Index Values and Quantitative HCV RNA Results in HCV IgG-Reactive Serum Samples
Conference Presentation
HCV Testing Overview
Publication
Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study
Publication
Hepatitis C Virus Testing During Pregnancy Following Universal Screening Recommendations
Test FAQ
Hepatitis C Viral RNA Genotype 1 NS5A Drug resistance
Test FAQ
Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.